Abstract 292P
Background
The potential role of circulating miRNAs as biomarkers for breast cancer (BC) has been widely reported. However, the large discrepancy between studies prevents the feasibility of implementing circulating miRNAs in routine clinical practice. In BC patients undergoing neoadjuvant chemotherapy (NAC), the ability to anticipate response could lead to improve prognosis by individualizing post-NAC approach. In this scenario, the present meta-analysis aims to quantify and clarify circulating miRNAs' predictive role for NAC response in BC patients.
Methods
We conducted a comprehensive literature search in 5 main medical databases until 16th February 2023, along with additional research sources. The systematic review and meta-analysis were performed in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses and we applied the Cochrane recommended methodology for prognostic factor studies. We quantitatively pooled the effect sizes of each study by applying a random-effects model to consider within and between-study variances. Cochrane Q test (significance at 0.05) and I2 value were used to assess between-study heterogeneity. The Prediction Model Risk Of Bias Assessment Tool evaluated studies' bias risk.
Results
The meta-analysis included 15 studies, with a total of 1521 early BC patients. Overall, our findings support the hypothesis that circulating miR-21-5p and miR-155-5p may act as predictive biomarkers. Pooled area under the curve values were 0.72 (95% confidence interval (CI) 0.59-0.86, p< 0.05) and 0.67 (95% CI 0.53-0.81, p< 0.05), respectively, thus indicating an acceptable predictive ability in anticipating NAC response.
Conclusions
To our knowledge, this is the first systematic review and meta-analysis that provides a quantitative synthesis of the predictive value of circulating miRNAs for NAC response in BC patients. However, due to the limited number of studies included in the meta-analyses and the high clinical and statistical heterogeneity, further studies are needed to confirm the predictive power of circulating miR-21-5p and miR-155-5p.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
304P - Generalizability of 313-SNP PRS for breast cancer risk in non-European ancestries
Presenter: Helen Shang
Session: Poster session 02
305P - Prognostic implications of HER2 changes after neoadjuvant chemotherapy in patients with HER2-zero and HER2-low breast cancer
Presenter: Sora Kang
Session: Poster session 02
307P - Identifying new biological subgroups of triple-negative breast cancer using next-generation integrative clustering pipeline
Presenter: Xixuan Zhu
Session: Poster session 02
308P - Regression-based deep-learning predicts breast cancer recurrence risk score from pathology slides
Presenter: Omar El Nahhas
Session: Poster session 02
310P - Longitudinal evaluation of circulating tumour DNA in early breast cancer using a plasma-only methylation-based assay
Presenter: Mitchell Elliott
Session: Poster session 02
311P - Multinational survey study assessing genetic testing and counselling among patients (pts) with breast cancer (MAGENTA): Results on the genetic counselling experience
Presenter: Ranjit Kaur
Session: Poster session 02
312P - Prediction model of breast cancer patient’s neoadjuvant treatment outcome using breast cancer organoids cultured from core needle biopsies
Presenter: Dong Woo Lee
Session: Poster session 02
313P - Intrinsic subtypes in a cohort of early breast cancer patients
Presenter: Theresa Bracht
Session: Poster session 02